AlphaGrep UK
KRYS icon

AlphaGrep UK’s Krystal Biotech KRYS Stock Holding History

AlphaGrep UK’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$252K Buy
+757
New +$262K 0.08% 578

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

AlphaGrep UK's KRYS Position: Q3 2026 in Review

AlphaGrep UK opened a new position in Krystal Biotech (KRYS) in Q3 2026: 757 shares worth $252K. The stake represents 0.08% of the portfolio and ranks #578 among its holdings.

353 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • AlphaGrep UK held 757 shares of Krystal Biotech worth $252K as of Q3 2026.
  • Krystal Biotech was a new AlphaGrep UK position in Q3 2026.
  • Krystal Biotech made up 0.08% of AlphaGrep UK's portfolio in Q3 2026, its #578 holding.
  • 353 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.